Contact this trialFirst, we need to learn more about you.
Proteasome Inhibitor
High-Dose Carfilzomib Combo for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
Middletown, New Jersey
This trial is testing whether carfilzomib, when given in high doses and alongside other drugs, is safe for patients and what the best tolerated dose is. The trial is also testing how much myeloma cells are left in the body after treatment (known as minimal residual disease or MRD).
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.